Anti-CD20/CD22 chimeric antigen receptor T cell therapy - Yake Biotechnology
Alternative Names: 'Anti-CD20/22 CAR-T cell therapy - Yake Biotechnology; Anti-CD20/22 CAR-T cells; CD20/CD22 dual Targeted CAR T-cell therapy - Yake BiotechnologyLatest Information Update: 28 Nov 2021
At a glance
- Originator Yake Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Haematological-malignancies(Second-line therapy or greater) in China (IV, Infusion)